The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
Breast neoplasms
Cohort study
Docetaxel
Return-to-work
Single nucleotide polymorphisms
Taxane
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
18
08
2022
accepted:
16
12
2022
pubmed:
5
1
2023
medline:
10
2
2023
entrez:
4
1
2023
Statut:
ppublish
Résumé
Breast cancer treatment is associated with adverse effects, which may delay return-to-work. Single nucleotide polymorphisms (SNPs) may influence the risk and severity of treatment toxicities, which in turn could delay return-to-work. We examined the association of 26 SNPs with return-to-work in premenopausal women with breast cancer. Using Danish registries, we identified premenopausal women diagnosed with non-distant metastatic breast cancer during 2007‒2011, assigned adjuvant combination chemotherapy including cyclophosphamide and docetaxel. We genotyped 26 SNPs in 20 genes (ABCB1, ABCC2, ABCG2, CYP1A1, CYP1B1, CYP3A, CYP3A4, CYP3A5, GSTP1, SLCO1B1, SLCO1B3, ARHGEF10, EPHA4, EPHA5, EPHA6, EPHA8, ERCC1, ERCC2, FGD4 and TRPV1) using TaqMan assays. We computed the cumulative incidence of return-to-work (defined as 4 consecutive weeks of work) up to 10 years after surgery, treating death and retirement as competing events and fitted cause-specific Cox regression models to estimate crude hazard ratios (HRs) and 95% confidence intervals (CIs) of return-to-work. We also examined stable labor market attachment (defined as 12 consecutive weeks of work). We included 1,964 women. No associations were found for 25 SNPs. The cumulative incidence of return-to-work varied by CYP3A5 rs776746 genotype. From 6 months to 10 years after surgery, return-to-work increased from 25 to 94% in wildtypes (n = 1600), from 17 to 94% in heterozygotes (n = 249), and from 7 to 82% in homozygotes (n = 15). The HR showed delayed return-to-work in CYP3A5 rs776746 homozygotes throughout follow-up (0.48, 95% CI 0.26, 0.86), compared with wildtypes. Estimates were similar for stable labor market attachment. Overall, the SNPs examined in the study did not influence return-to-work or stable labor market attachment after breast cancer in premenopausal women. Our findings did suggest that the outcomes were delayed in homozygote carriers of CYP3A5 rs776746, though the number of homozygotes was low.
Identifiants
pubmed: 36598552
doi: 10.1007/s00280-022-04499-z
pii: 10.1007/s00280-022-04499-z
pmc: PMC9905159
doi:
Substances chimiques
Cytochrome P-450 CYP3A
EC 1.14.14.1
taxane
1605-68-1
Taxoids
0
ERCC2 protein, human
EC 5.99.-
Xeroderma Pigmentosum Group D Protein
EC 3.6.4.12
SLCO1B1 protein, human
0
Liver-Specific Organic Anion Transporter 1
0
FGD4 protein, human
0
Microfilament Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
157-165Informations de copyright
© 2023. The Author(s).
Références
International Agency for Research on Cancer (2020) Latest global cancer data: Cancer burden rises to 19.3 million new cases. Press release N° 292. World Health Organization
Lundh MH, Lampic C, Nordin K, Ahlgren J, Bergkvist L, Lambe M et al (2013) Changes in health-related quality of life by occupational status among women diagnosed with breast cancer—a population-based cohort study. Psychooncology 22:2321–2331
doi: 10.1002/pon.3285
Cocchiara RA, Sciarra I, D’Egidio V, Sestili C, Mancino M, Backhaus I et al (2018) Returning to work after breast cancer: a systematic review of reviews. Work 61:463–476
doi: 10.3233/WOR-182810
Arndt V, Koch-Gallenkamp L, Bertram H, Eberle A, Holleczek B, Pritzkuleit R et al (2019) Return to work after cancer. A multi-regional population-based study from Germany. Acta Oncol Stockh Swed. 58:811–818
doi: 10.1080/0284186X.2018.1557341
Islam T, Dahlui M, Majid HA, Nahar AM, Mohd Taib NA, Su TT (2014) Factors associated with return to work of breast cancer survivors: a systematic review. BMC Public Health 14:S8
doi: 10.1186/1471-2458-14-S3-S8
Sun W, Chen K, Terhaar A, Wiegmann DA, Heidrich SM, Tevaarwerk AJ et al (2016) Work-related barriers, facilitators, and strategies of breast cancer survivors working during curative treatment. Work Read Mass 55:783–795
Bijker R, Duijts SFA, Smith SN, de Wildt-Liesveld R, Anema JR, Regeer BJ (2018) Functional impairments and work-related outcomes in breast cancer survivors: a systematic review. J Occup Rehabil 28:429–451
doi: 10.1007/s10926-017-9736-8
Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL et al (2018) Breast Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf . Accessed 9 Oct 2018
de Boer AGEM (2014) The European Cancer and Work Network: CANWON. J Occup Rehabil 24:393–398
doi: 10.1007/s10926-013-9474-5
Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S et al (2017) Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer 123:759–768
doi: 10.1002/cncr.30421
Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol Stockh Swed 54:587–591
doi: 10.3109/0284186X.2014.995775
Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642
doi: 10.1200/JCO.2005.04.0543
Eckhoff L, Nielsen M, Moeller S, Knoop A (2011) TAXTOX—a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol Stockh Swed 50:1075–1082
doi: 10.3109/0284186X.2011.602111
Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C et al (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099–5109
doi: 10.1158/1078-0432.CCR-12-1590
Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS et al (2015) Association of the Charcot–Marie–Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 357:35–40
doi: 10.1016/j.jns.2015.06.056
Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK (2015) Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol Stockh Swed 54:530–537
Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S et al (2016) Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel. OncoTargets Ther 9:5073–5080
doi: 10.2147/OTT.S106574
Ahern TP, Collin LJ, Baurley JW, Kjærsgaard A, Nash R, Maliniak ML et al (2020) Metabolic pathway analysis and effectiveness of tamoxifen in Danish breast cancer patients. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 29:582–590
doi: 10.1158/1055-9965.EPI-19-0833
Howell A (2005) ATAC trial update. Lancet 365:1225–1226
doi: 10.1016/S0140-6736(05)74803-0
Schmidt M, Schmidt SAJ, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V et al (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563–591
doi: 10.2147/CLEP.S179083
Schmidt M, Pedersen L, Sørensen HT (2014) The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 29:541–549
doi: 10.1007/s10654-014-9930-3
Jensen M-B, Laenkholm A-V, Offersen BV, Christiansen P, Kroman N, Mouridsen HT et al (2018) The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016. Acta Oncol 57:13–18
doi: 10.1080/0284186X.2017.1404638
Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L (2010) Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol 2:51–56
doi: 10.2147/CLEP.S9908
Helweg-Larsen K (2011) The Danish Register of causes of death. Scand J Public Health 39(7 Suppl):26–29
doi: 10.1177/1403494811399958
Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT (2015) The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 7:449–490
doi: 10.2147/CLEP.S91125
Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff-Roos J (2018) The Danish medical birth register. Eur J Epidemiol 33:27–36
doi: 10.1007/s10654-018-0356-1
Jensen VM, Rasmussen AW (2011) Danish education registers. Scand J Public Health 39(7 Suppl):91–94
doi: 10.1177/1403494810394715
Baadsgaard M, Quitzau J (2011) Danish registers on personal income and transfer payments. Scand J Public Health 39(7_suppl):103–105
doi: 10.1177/1403494811405098
Andersen TM, Svarer M (2007) Flexicurity—labour market performance in Denmark*. CESifo Econ Stud 53:389–429
doi: 10.1093/cesifo/ifm015
Hjollund NH, Larsen FB, Andersen JH (2007) Register-based follow-up of social benefits and other transfer payments: accuracy and degree of completeness in a Danish interdepartmental administrative database compared with a population-based survey. Scand J Public Health 35:497–502
doi: 10.1080/14034940701271882
Collin LJ, Cronin-Fenton DP, Ahern TP, Christiansen PM, Damkier P, Ejlertsen B et al (2018) Cohort Profile: the Predictors of Breast Cancer Recurrence (ProBe CaRE) Premenopausal Breast Cancer Cohort Study in Denmark. BMJ Open. https://doi.org/10.1136/bmjopen-2018-021805
doi: 10.1136/bmjopen-2018-021805
Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen M-B, Knoop AS, Højris I et al (2017) Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol 35:2639–2646
doi: 10.1200/JCO.2017.72.3494
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q et al (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581:434–443
doi: 10.1038/s41586-020-2308-7
Rasmus R, Chih W, Kristian K, Fosbøl EL, Mogensen UM, Lamberts M et al (2016) Return to the workforce after first hospitalization for heart failure. Circulation 134:999–1009
doi: 10.1161/CIRCULATIONAHA.116.021859
Kristian K, Mads W, Normark MR, Kirsten F, Eggert JS, Shahzleen R et al (2015) Return to work in out-of-hospital cardiac arrest survivors. Circulation 131:1682–1690
doi: 10.1161/CIRCULATIONAHA.114.011366
Evers PD, Farkas DK, Hjorth CF, Khoury M, Olsen M, Madsen NL (2021) Return to work following adverse cardiovascular events in adults with congenital heart disease. Int J Cardiol Congenit Heart Dis 4:100160
doi: 10.1016/j.ijcchd.2021.100160
Biering K, Hjøllund NH, Lund T (2013) Methods in measuring return to work: a comparison of measures of return to work following treatment of coronary heart disease. J Occup Rehabil 23:400–405
doi: 10.1007/s10926-012-9405-x
Amin MB, American Joint Committee on Cancer, American Cancer Society, editors (2017) AJCC cancer staging manual. Eight edition / editor-in-chief, Mahul B. Amin, MD, FCAP ; editors, Stephen B. Edge, MD, FACS [and 16 others] ; Donna M. Gress, RHIT, CTR-Technical editor ; Laura R. Meyer, CAPM-Managing editor. American Joint Committee on Cancer, Springer, Chicago
Rothman KJ, Lash T, Greenland S (2012) Modern Epidemiology. Third edition. Philadelphia Baltimore New York London Buenos Aires Hong Kong Sydney Tokyo: LWW
Kollerup A, Ladenburg J, Heinesen E, Kolodziejczyk C (2021) The importance of workplace accommodation for cancer survivors—the role of flexible work schedules and psychological help in returning to work. Econ Hum Biol 43:101057
doi: 10.1016/j.ehb.2021.101057
Baker SD, Verweij J, Cusatis GA, van Schaik R, Marsh S, Orwick SJ et al (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85:155–163
doi: 10.1038/clpt.2008.95
Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S et al (2011) Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11:121–129
doi: 10.1038/tpj.2010.13
Eckhoff L, Knoop A, Jensen MB, Ewertz M (1990) Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eur J Cancer Oxf Engl 2015(51):292–300
Argyriou AA, Polychronopoulos P, Iconomou G, Koutras A, Kalofonos HP, Chroni E (2005) Paclitaxel plus carboplatin–induced peripheral neuropathy: a prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 252:1459–1464
doi: 10.1007/s00415-005-0887-8
Cronin-Fenton DP, Kjærsgaard A, Ahern TP, Mele M, Ewertz M, Hamilton-Dutoit S et al (2017) Validity of Danish Breast Cancer Group (DBCG) registry data used in the predictors of breast cancer recurrence (ProBeCaRe) premenopausal breast cancer cohort study. Acta Oncol 56:1155–1160
doi: 10.1080/0284186X.2017.1327720
Jensen AR, Storm HH, Møller S, Overgaard J (2003) Validity and representativity in the Danish Breast Cancer Cooperative Group—a study on protocol allocation and data validity from one county to a multi-centre database. Acta Oncol Stockh Swed 42:179–185
doi: 10.1080/02841860310000737
Stapelfeldt CM, Jensen C, Andersen NT, Fleten N, Nielsen CV (2012) Validation of sick leave measures: self-reported sick leave and sickness benefit data from a Danish national register compared to multiple workplace-registered sick leave spells in a Danish municipality. BMC Public Health 12:661
doi: 10.1186/1471-2458-12-661
Salanti G, Amountza G, Ntzani EE, Ioannidis JPA (2005) Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet EJHG 13:840–848
doi: 10.1038/sj.ejhg.5201410
Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2008) How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol 37:136–146
doi: 10.1093/ije/dym234
Hertz DL, Kidwell KM, Thibert JN, Gersch CL, Regan MM, Skaar TC et al (2015) Comparison of genotyping performance in DNA extracted from matched FFPE tumor, FFPE lymph node, and whole blood for pharmacogenetic analyses. J Clin Oncol 33(15_suppl):1528–1528
doi: 10.1200/jco.2015.33.15_suppl.1528
Hertz DL, Kidwell KM, Thibert JN, Gersch C, Regan MM, Skaar TC et al (2015) Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol 9:1868–1876
doi: 10.1016/j.molonc.2015.07.002
Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sørensen HT et al (2010) Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2:241–246
doi: 10.2147/CLEP.S13811
Cyclophosphamide Pathway, Pharmacokinetics. PharmGKB. https://www.pharmgkb.org/pathway/PA2034 . Accessed 12 Nov 2021
Jensen L, Overgaard C, Bøggild H, Garne JP, Lund T, Overvad K et al (2017) The Long-term financial consequences of breast cancer: a Danish registry-based cohort study Laura Jensen. Eur J Public Health. https://doi.org/10.1093/eurpub/ckx187.690
doi: 10.1093/eurpub/ckx187.690
Baurley JW, Kjærsgaard A, Zwick ME, Cronin-Fenton DP, Collin LJ, Damkier P et al (2020) Bayesian pathway analysis for complex interactions. Am J Epidemiol 189:1610–1622
doi: 10.1093/aje/kwaa130